2019 is set to be a significant year for the development of drug delivery systems, particularly focused on cancer immunotherapy. Our latest whitepaper considers recent work in the field and details the extensive research N4 Pharma has been doing to develop Nuvec®, a unique non-viral adjuvant delivery system for vaccines and cancer treatments.

Enter your details below to download the full paper.

N4 Pharma needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.